Meridigen holds the world-class techniques of GMP-standardized cell therapeutic drugs manufacturing and quality control systems. Meridigen has established stem cell identity identification platforms including umbilical cord-derived stem cells isolation, expansion, characterization, potency and efficacy and also performed stem cell fundamental studies as well as preclinical pharmacological studies.

Research Progress

Meridigen has been conducting investigational new drug (IND) application and planning clinical trials of the therapeutics drugs for pulmonary diseases and neurological diseases including bronchopulmonary dysplasia (BPD), chronic obstructive pulmonary disease (COPD), ischemic stroke, and cerebral palsy (CP).

Technology

Meridigen has exclusive manufacturing technologies and state-of-the-art equipment in establishment of cell bank, large-scale culturing, harvesting, and development of cryo-preservation as well as pharmaceutical formulation. Meridigen independent develops mesenchymal stem cells isolation and purification technologies which have been patented in USA and Taiwan. Meridigen also skills in stem cell–related techniques that have been protected by global patent strategies, including:

• Stem cells analysis and characterization platform
• Stem cells scaling up platform

Collaborators

Meridigen has formed strong collaborations with renowned academic institutions, including Industrial Technology Research Institute (ITRI) Biomedical Research Centre, National Chiao Tung University (NCTU), Taipei Medical University (TMU), Southern Taiwan University of Science and Technology (STUST), and National Dong Hwa University (NDHU), to accelerate stem cell drugs development and be a global leader in stem cell-based therapeutic drugs. In addition, Meridigen also collaborates with leading medical centres in Taiwan, including Cardinal Tien Hospital, E-Da Hospital, and Chi Mei Hospital, to move from preclinical pharmacological studies forward to human clinical trials.